Gerard Wallace's Contact Details

Gerard Wallace's Company Details

Toku Eyes

N/A, N/A, NZ • 5 - 9 Employees
Medical Equipment

Toku Eyes artificial intelligence (AI) engine THEIA has grown since inception in 2018 & seeks to address cardiovascular & ocular disease manifest in the fundus. THEIA's capabilities range from screening, diagnosing & prognosing these various diseases.Our mission is to eliminate preventable health & vision deterioration, & have no relevant disease missed during consultation. Early, accessable & affordable screening, diagnosis & prognosis of disease are our goals. Every consultation could become a Specialist consultation, regardless of where & with whom the patient consults.THEIA is a unique set of AI engines, each specialised in using different imaging modalities for diagnostic, prognostic or health assessment purposes. Image enhancement & other quality parameters are designed into THEIA. It would be a valuable tool for every Eye Healthcare Clinician to help them rapidly identify & action high priority diseases.Millions of parameters are reviewed by THEIA in every image, delivering high sensitivity, specificity & negative predictive values. The diagnostic report is provided in 10 seconds. THEIA's broader attributes can be seen in its ability to determine HbA1c levels & cardiovascular risk factors via the eye, with associated prognostic capability. THEIA in use replicates the way medical Specialists step through a diagnosis. It has been tested on more than 66,000 patients. Implementation of THEIA is intended to augment Clinicians' capabilities, automating mundane tasks performed during a routine eye & health check. THEIA is future-proofed for various imaging modalities & is automated end-to-end from captured image quality check to the final patient-referral letter & report generation. It is device/software platform/ clinician –agnostic & utilises secure & scalable, encrypted Cloud hosting. Regulatory approval submissions are in preparation for the major agencies.Toku Eyes welcomes enquiries from potential clinical, commercial & research partners.